Novartis obtained approval from the European Commission to market its once-daily Ultibro Breezhaler, or QVA149, as a maintenance therapy for chronic obstructive pulmonary disease. The Japanese Ministry of Health, Labour and Welfare approved Ultibro Inhalation Capsules, delivered using the Breezhaler device, to treat symptoms of COPD.

Full Story:
PharmaTimes (U.K.)

Related Summaries